MDCX
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Medicus Pharma submits an optimized registration protocol for Teverelix to the FDA to establish a partner-ready program in advanced prostate cancerSep 29, 2026
- Medicus Pharma announced an exclusive development focus for SkinJect in Gorlin syndrome following a commercial, clinical, and regulatory assessmentSep 21, 2026
- Medicus Pharma published abridged final Phase 2 SkinJect results identifying the 200 µg D-MNA patch as the lead development doseSep 10, 2026
- Medicus Pharma receives FDA 'Study May Proceed' clearance for registrational SkinJect studyJul 27, 2026
- Medicus Pharma submitted a request for Rare Pediatric Disease Designation for SkinJect in Gorlin syndromeJun 15, 2026